Entertainment
Compare Stocks
5 / 10Stock Comparison
CNK vs AMC vs IMAX vs MCS vs RGC
Revenue, margins, valuation, and 5-year total return — side by side.
Entertainment
Entertainment
Entertainment
Drug Manufacturers - Specialty & Generic
CNK vs AMC vs IMAX vs MCS vs RGC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Entertainment | Entertainment | Entertainment | Entertainment | Drug Manufacturers - Specialty & Generic |
| Market Cap | $3.15B | $973M | $1.93B | $565M | $13.48B |
| Revenue (TTM) | $3.12B | $5.03B | $405M | $764M | $0.00 |
| Net Income (TTM) | $138M | $-547M | $43M | $14M | $-5M |
| Gross Margin | 40.7% | 75.3% | 58.1% | 113.7% | — |
| Operating Margin | 11.0% | 46.5% | 21.4% | 2.4% | — |
| Forward P/E | 12.7x | — | 21.2x | 32.0x | — |
| Total Debt | $3.78B | $8.14B | $297M | $335M | $86K |
| Cash & Equiv. | $344M | $429M | $151M | $23M | $3M |
CNK vs AMC vs IMAX vs MCS vs RGC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 21 | May 26 | Return |
|---|---|---|---|
| Cinemark Holdings, … (CNK) | 100 | 178.6 | +78.6% |
| AMC Entertainment H… (AMC) | 100 | 0.4 | -99.6% |
| IMAX Corporation (IMAX) | 100 | 221.1 | +121.1% |
| The Marcus Corporat… (MCS) | 100 | 111.9 | +11.9% |
| Regencell Bioscienc… (RGC) | 100 | 11433.9 | +11333.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CNK vs AMC vs IMAX vs MCS vs RGC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
CNK has the current edge in this matchup, primarily because of its strength in defensive.
- Beta 0.22, yield 1.1%, current ratio 0.71x
- Better valuation composite
- Beta 0.22 vs AMC's 1.82
Among these 5 stocks, AMC doesn't own a clear edge in any measured category.
IMAX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 16.5%, EPS growth 31.3%, 3Y rev CAGR 10.9%
- 10.7% margin vs AMC's -10.9%
- 4.9% ROA vs RGC's -60.2%, ROIC 12.7% vs -43.8%
MCS is the clearest fit if your priority is income & stability.
- Dividend streak 3 yrs, beta 0.85, yield 1.6%
- 1.6% yield, 3-year raise streak, vs CNK's 1.1%, (3 stocks pay no dividend)
RGC ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.
- 104.1% 10Y total return vs IMAX's 9.0%
- Lower volatility, beta 0.72, Low D/E 1.0%, current ratio 41.92x
- 100.0% revenue growth vs CNK's 2.1%
- +10.2% vs AMC's -39.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 100.0% revenue growth vs CNK's 2.1% | |
| Value | Better valuation composite | |
| Quality / Margins | 10.7% margin vs AMC's -10.9% | |
| Stability / Safety | Beta 0.22 vs AMC's 1.82 | |
| Dividends | 1.6% yield, 3-year raise streak, vs CNK's 1.1%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +10.2% vs AMC's -39.8% | |
| Efficiency (ROA) | 4.9% ROA vs RGC's -60.2%, ROIC 12.7% vs -43.8% |
CNK vs AMC vs IMAX vs MCS vs RGC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
CNK vs AMC vs IMAX vs MCS vs RGC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
IMAX leads in 1 of 6 categories
AMC leads 1 • RGC leads 1 • MCS leads 1 • CNK leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
IMAX leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
AMC and RGC operate at a comparable scale, with $5.0B and $0 in trailing revenue. IMAX is the more profitable business, keeping 10.7% of every revenue dollar as net income compared to AMC's -10.9%. On growth, AMC holds the edge at +21.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $3.1B | $5.0B | $405M | $764M | $0 |
| EBITDAEarnings before interest/tax | $545M | $2.6B | $150M | $88M | -$4M |
| Net IncomeAfter-tax profit | $138M | -$547M | $43M | $14M | -$5M |
| Free Cash FlowCash after capex | $177M | -$124M | $115M | $37M | -$7M |
| Gross MarginGross profit ÷ Revenue | +40.7% | +75.3% | +58.1% | +113.7% | — |
| Operating MarginEBIT ÷ Revenue | +11.0% | +46.5% | +21.4% | +2.4% | — |
| Net MarginNet income ÷ Revenue | +4.4% | -10.9% | +10.7% | +1.9% | — |
| FCF MarginFCF ÷ Revenue | +5.7% | -2.5% | +28.5% | +4.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -4.7% | +21.2% | -6.1% | +3.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -18.2% | +53.2% | +65.5% | +3.8% | — |
Valuation Metrics
AMC leads this category, winning 2 of 6 comparable metrics.
Valuation Metrics
At 26.0x trailing earnings, CNK trades at a 54% valuation discount to IMAX's 56.7x P/E. On an enterprise value basis, AMC's 4.7x EV/EBITDA is more attractive than IMAX's 13.1x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $3.2B | $973M | $1.9B | $565M | $13.5B |
| Enterprise ValueMkt cap + debt − cash | $6.6B | $8.7B | $2.1B | $877M | $13.5B |
| Trailing P/EPrice ÷ TTM EPS | 25.96x | -1.29x | 56.73x | 44.24x | -3134.48x |
| Forward P/EPrice ÷ next-FY EPS est. | 12.74x | — | 21.21x | 31.96x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 12.12x | 4.69x | 13.13x | 9.55x | — |
| Price / SalesMarket cap ÷ Revenue | 1.01x | 0.20x | 4.70x | 0.75x | — |
| Price / BookPrice ÷ Book value/share | 8.76x | — | 4.64x | 1.24x | 1640.70x |
| Price / FCFMarket cap ÷ FCF | 17.80x | — | 16.23x | 571.49x | — |
Profitability & Efficiency
Evenly matched — IMAX and RGC each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
CNK delivers a 25.4% return on equity — every $100 of shareholder capital generates $25 in annual profit, vs $-67 for RGC. RGC carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to CNK's 9.14x. On the Piotroski fundamental quality scale (0–9), IMAX scores 7/9 vs AMC's 3/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +25.4% | — | +10.8% | +2.4% | -67.0% |
| ROA (TTM)Return on assets | +3.0% | -6.9% | +4.9% | +1.4% | -60.2% |
| ROICReturn on invested capital | +7.5% | +23.7% | +12.7% | +2.1% | -43.8% |
| ROCEReturn on capital employed | +9.3% | +29.0% | +14.5% | +2.5% | -46.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 3 | 7 | 7 | 4 |
| Debt / EquityFinancial leverage | 9.14x | — | 0.70x | 0.73x | 0.01x |
| Net DebtTotal debt minus cash | $3.4B | $7.7B | $146M | $312M | -$3M |
| Cash & Equiv.Liquid assets | $344M | $429M | $151M | $23M | $3M |
| Total DebtShort + long-term debt | $3.8B | $8.1B | $297M | $335M | $85,741 |
| Interest CoverageEBIT ÷ Interest expense | 1.89x | 0.35x | 21.15x | 6.90x | — |
Total Returns (Dividends Reinvested)
RGC leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RGC five years ago would be worth $986,970 today (with dividends reinvested), compared to $173 for AMC. Over the past 12 months, RGC leads with a +1017.6% total return vs AMC's -39.8%. The 3-year compound annual growth rate (CAGR) favors RGC at 2.4% vs AMC's -70.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +15.1% | -1.2% | -0.8% | +19.5% | +32.8% |
| 1-Year ReturnPast 12 months | -8.2% | -39.8% | +46.8% | +12.6% | +1017.6% |
| 3-Year ReturnCumulative with dividends | +69.9% | -97.3% | +86.2% | +14.8% | +3908.5% |
| 5-Year ReturnCumulative with dividends | +29.8% | -98.3% | +72.8% | +2.6% | +9769.7% |
| 10-Year ReturnCumulative with dividends | -8.2% | -84.6% | +9.0% | +7.9% | +10406.7% |
| CAGR (3Y)Annualised 3-year return | +19.3% | -70.0% | +23.0% | +4.7% | +2.4% |
Risk & Volatility
Evenly matched — CNK and MCS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CNK is the less volatile stock with a 0.22 beta — it tends to amplify market swings less than AMC's 1.82 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCS currently trades 90.6% from its 52-week high vs RGC's 32.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.22x | 1.82x | 0.43x | 0.85x | 0.72x |
| 52-Week HighHighest price in past year | $34.01 | $4.08 | $43.16 | $20.02 | $83.60 |
| 52-Week LowLowest price in past year | $21.60 | $0.93 | $22.54 | $12.85 | $1.59 |
| % of 52W HighCurrent price vs 52-week peak | +79.4% | +39.0% | +82.8% | +90.6% | +32.6% |
| RSI (14)Momentum oscillator 0–100 | 38.7 | 48.7 | 39.3 | 39.3 | 46.5 |
| Avg Volume (50D)Average daily shares traded | 2.1M | 29.5M | 1.2M | 140K | 134K |
Analyst Outlook
MCS leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: CNK as "Buy", AMC as "Hold", IMAX as "Buy", MCS as "Buy", RGC as "Hold". Consensus price targets imply 26.8% upside for MCS (target: $23) vs 17.3% for CNK (target: $32). For income investors, MCS offers the higher dividend yield at 1.61% vs CNK's 1.07%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Hold | Buy | Buy | Hold |
| Price TargetConsensus 12-month target | $31.67 | $2.00 | $43.00 | $23.00 | — |
| # AnalystsCovering analysts | 31 | 28 | 25 | 8 | 4 |
| Dividend YieldAnnual dividend ÷ price | +1.1% | — | — | +1.6% | — |
| Dividend StreakConsecutive years of raises | 0 | 0 | 1 | 3 | — |
| Dividend / ShareAnnual DPS | $0.29 | — | — | $0.29 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +8.7% | 0.0% | +0.1% | +3.3% | 0.0% |
IMAX leads in 1 of 6 categories (Income & Cash Flow). AMC leads in 1 (Valuation Metrics). 2 tied.
CNK vs AMC vs IMAX vs MCS vs RGC: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is CNK or AMC or IMAX or MCS or RGC a better buy right now?
For growth investors, IMAX Corporation (IMAX) is the stronger pick with 16.
5% revenue growth year-over-year, versus 2. 1% for Cinemark Holdings, Inc. (CNK). Cinemark Holdings, Inc. (CNK) offers the better valuation at 26. 0x trailing P/E (12. 7x forward), making it the more compelling value choice. Analysts rate Cinemark Holdings, Inc. (CNK) a "Buy" — based on 31 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CNK or AMC or IMAX or MCS or RGC?
On trailing P/E, Cinemark Holdings, Inc.
(CNK) is the cheapest at 26. 0x versus IMAX Corporation at 56. 7x. On forward P/E, Cinemark Holdings, Inc. is actually cheaper at 12. 7x.
03Which is the better long-term investment — CNK or AMC or IMAX or MCS or RGC?
Over the past 5 years, Regencell Bioscience Holdings Limited (RGC) delivered a total return of +97.
7%, compared to -98. 3% for AMC Entertainment Holdings, Inc. (AMC). Over 10 years, the gap is even starker: RGC returned +104. 1% versus AMC's -84. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CNK or AMC or IMAX or MCS or RGC?
By beta (market sensitivity over 5 years), Cinemark Holdings, Inc.
(CNK) is the lower-risk stock at 0. 22β versus AMC Entertainment Holdings, Inc. 's 1. 82β — meaning AMC is approximately 735% more volatile than CNK relative to the S&P 500. On balance sheet safety, Regencell Bioscience Holdings Limited (RGC) carries a lower debt/equity ratio of 1% versus 9% for Cinemark Holdings, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — CNK or AMC or IMAX or MCS or RGC?
By revenue growth (latest reported year), IMAX Corporation (IMAX) is pulling ahead at 16.
5% versus 2. 1% for Cinemark Holdings, Inc. (CNK). On earnings-per-share growth, the picture is similar: The Marcus Corporation grew EPS 270. 8% year-over-year, compared to -49. 5% for Cinemark Holdings, Inc.. Over a 3-year CAGR, IMAX leads at 10. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — CNK or AMC or IMAX or MCS or RGC?
IMAX Corporation (IMAX) is the more profitable company, earning 8.
5% net margin versus -13. 0% for AMC Entertainment Holdings, Inc. — meaning it keeps 8. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMC leads at 38. 1% versus 0. 0% for RGC. At the gross margin level — before operating expenses — AMC leads at 75. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is CNK or AMC or IMAX or MCS or RGC more undervalued right now?
On forward earnings alone, Cinemark Holdings, Inc.
(CNK) trades at 12. 7x forward P/E versus 32. 0x for The Marcus Corporation — 19. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCS: 26. 8% to $23. 00.
08Which pays a better dividend — CNK or AMC or IMAX or MCS or RGC?
In this comparison, MCS (1.
6% yield), CNK (1. 1% yield) pay a dividend. AMC, IMAX, RGC do not pay a meaningful dividend and should not be held primarily for income.
09Is CNK or AMC or IMAX or MCS or RGC better for a retirement portfolio?
For long-horizon retirement investors, Cinemark Holdings, Inc.
(CNK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 22), 1. 1% yield). AMC Entertainment Holdings, Inc. (AMC) carries a higher beta of 1. 82 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CNK: -8. 2%, AMC: -84. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between CNK and AMC and IMAX and MCS and RGC?
These companies operate in different sectors (CNK (Communication Services) and AMC (Communication Services) and IMAX (Communication Services) and MCS (Communication Services) and RGC (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: CNK is a small-cap quality compounder stock; AMC is a small-cap quality compounder stock; IMAX is a small-cap high-growth stock; MCS is a small-cap quality compounder stock; RGC is a mid-cap quality compounder stock. CNK, MCS pay a dividend while AMC, IMAX, RGC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
- Sector: Communication Services
- Market Cap > $100B
- Gross Margin > 24%
- Dividend Yield > 0.5%
- Sector: Communication Services
- Market Cap > $100B
- Revenue Growth > 10%
- Gross Margin > 45%
- Sector: Communication Services
- Market Cap > $100B
- Gross Margin > 68%
- Dividend Yield > 0.6%
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.